Results 21 to 30 of about 1,641 (202)
Type 2 diabetes and heart failure: insights from the global DISCOVER study. [PDF]
ESC Heart Fail, 2021 Abstract Aims Heart failure (HF) is increasingly recognized as a major cause of morbidity and mortality in patients with type 2 diabetes (T2D), but the global epidemiology and treatment of HF in T2D are not well defined. This study aimed to examine the global prevalence of HF and the incidence of HF over 3 years of follow‐up in patients with T2D [by ...
Arnold SV +22 more
europepmc +2 more sources
Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study. [PDF]
J Diabetes Investig, 2021 We investigated the cardiovascular outcomes in Japanese patients with type 2 diabetes initiating sodium–glucose cotransporter 2 inhibitors matched 1:1 to patients initiating other glucose‐lowering drugs. Sodium–glucose cotransporter 2 inhibitor initiation was associated with lower risks of in‐hospital death, hospitalization for heart failure and the ...
Kohsaka S +7 more
europepmc +2 more sources
Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study. [PDF]
Diabetes Obes Metab, 2021 Abstract Aim To investigate global patterns of cardiovascular risk factor control in patients with type 2 diabetes mellitus (T2D). Methods DISCOVER is an international, observational cohort study of patients with T2D beginning second‐line glucose‐lowering therapy.
Patel KK +16 more
europepmc +2 more sources
Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea). [PDF]
Diabetes Obes Metab, 2021 Abstract Aims To investigate the effectiveness of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors on the risk of progression to end‐stage renal disease (ESRD) and all‐cause mortality in a broad range of patients with type 2 diabetes (T2D) using a Korean nationwide cohort.
Koh ES +8 more
europepmc +2 more sources
Aporie del mito greco e lineamenti della questione fenicia
Cartagine. Studi e Ricerche, 2023 Chi furono i Fenici, nei miti greci? L’esame della rappresentazione dei personaggi “fenici” in alcuni casi di studio, tratti in particolare da Omero, Erodoto, Platone, Ergia di Rodi e Filone di Biblo, consente di sviluppare alcune riflessioni sulle ...
Sergio Ribichini
doaj +1 more source
Cartagine. Studi e Ricerche, 2022 Presentazione del volume M. Guirguis - S. Muscuso - R. Pla Orquín (eds), Cartagine, il Mediterraneo centro-occidentale e la Sardegna. Società, economia e cultura materiale tra Fenici e autoctoni.
Federico Mazza, Federica Spagnoli
doaj +1 more source
Diabetes, Obesity and Metabolism, Volume 25, Issue 7, Page 1890-1899, July 2023., 2023 Abstract Aim To identify distinct HbA1c trajectories in people with type 2 diabetes (T2D) starting second‐line glucose‐lowering therapy. Materials and Methods DISCOVER was a 3‐year observational study of individuals with T2D beginning second‐line glucose‐lowering therapy.
Brenda Bongaerts +14 more
wiley +1 more source
Pseudo-V1 ECG lead recording with quality smartwatches and medical interpretation may be necessary for timely and accurate remote detection of atrial flutter/fibrillation [PDF]
Eur Heart J, 2022 BACKGROUND: Remote rhythm monitoring with wearable devices is increasingly used especially for early detection of atrial fibrillation/flutter (AF/Afl), being the access to hospital discouraged, especially for frail elderly patients, due to the burden and
Brisinda, D +5 more
europepmc +2 more sources
Annals of Noninvasive Electrocardiology, Volume 26, Issue 6, November 2021., 2021 Abstract Background The magnetocardiography (MCG) functional localization can transfer the biomagnetic signal to the electrical activity information inside the heart. The electrical activity is directly related to the physiological function of the heart.
Zhihong Lu +2 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 23, Issue 8, Page 1956-1960, August 2021., 2021 Abstract We report the prevalence and change in severity of chronic kidney disease (CKD) in DISCOVER, a global, 3‐year, prospective, observational study of patients with type 2 diabetes (T2D) initiating second‐line glucose‐lowering therapy. CKD stages were defined according to estimated glomerular filtration rate (eGFR).
Kamlesh Khunti +19 more
wiley +1 more source